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Abstract 
Background: Hearing impairment, as one of the most common birth defects, is a hidden disability with negative impacts on speech andcognitive development.
Objectives: The aim of this study was to assess the prevalence of sensorineural hearing loss (SNHL) and determine the associated riskfactors among infants admitted to neonatal intensive care units (NICUs) and neonatal wards of teaching hospitals, affiliated to GolestanUniversity of Medical Sciences, Gorgan, Iran.
Patients and Methods: In this cross-sectional study, 791 infants were recruited via non-random sampling. Demographic and clinicalcharacteristics of the subjects were gathered, and the Automated Auditory Brainstem Response (AABR) test was performed uponadmission. Afterwards, the subjects were followed-up and re-assessed, using the AABR test. For infants with abnormal AABR results, theAuditory Brainstem Response (ABR) test was performed on the day of discharge.
Results: The mean age of the infants was 3.75 ± 4.86 days upon admission, and 56.4% of the subjects were female. The mean length ofhospital stay was 9.63 ± 1.1 days; the subjects were hospitalized for 3.50 ± 10.21 days in the NICUs and 6.1 ± 5.27 days in the neonatal wards. Intotal, 3.4% of the infants presented with SNHL. No significant difference was found between SNHL and neonates’ age (P = 0.52), sex (P = 0.5),or sepsis (P = 0.94). However, SNHL was significantly associated with gestational age (P = 0.045), birth weight (P < 0.001), length of hospitalstay (P < 0.001), pathological jaundice (P=0.033), antibiotic treatments (P = 0.007), and total serum bilirubin level (P = 0.01). Additionally,binary logistic regression analysis demonstrated the association between SNHL and these factors.
Conclusions: In this study, the prevalence of SNHL among hospitalized neonates was similar to previous reports in Iran and othercountries. Based on the findings, administration of ototoxic drugs during the neonatal period can lead to SNHL. Therefore, it seemsessential to regularly screen newborns under treatment and limit the indiscriminate use of ototoxic drugs. 
Keywords: Infant, Iran, Newborn, Sensorineural Hearing Loss 
1. BackgroundHearing impairment is described as reduced ability toapprehend sounds (1). The prevalence of hearing loss, defined as bilateral hearing loss > 60 db, is estimated at 1 case per 1000 individuals. If the threshold for bilat­eral hearing loss is considered to be more than 40 db, the prevalence of this impairment increases to 3 cases per 1000 individuals (2).Diagnosis of hearing impairment in infants and neo­nates is not simply possible through regular clinical ex­aminations. In fact, considering the delayed languagedevelopment in these neonates, severe hearing loss is notusually diagnosed until 18 to 24 months of life (3-5). Mild or moderate hearing loss is also not recognized until 48months of infant’s life (6, 7). 
The first three years of every individual’s life is deemed tobe a critical stage for language development. If an infant isnot exposed to language input during this golden perioddue to hearing impairment, his/her language skills, read­ing ability, and learning progress will be negatively affect­ed. Hearing loss also leads to cognitive, verbal, emotional,and psychological disabilities in the infants (8-10).Approximately, 20% - 30% of children with hearing loss show no initial symptoms. As a result, implementation ofhearing screening programs is quite essential. Based onsome previous studies, more than 50% of children with hearing defects have no known risk factors (11-16). Also, 30% of children with learning disabilities are somehow affected by hearing defects (17). 
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Today, many organizations have endorsed the nation­wide execution of hearing screening programs at birthand before hospital discharge. Considering the impor­tance of these programs, various states in the UnitedStates have passed the required legislations (18, 19).Early diagnosis of hearing loss before the presenta­tion of symptoms or complications is essential for thehealth of an individual. Moreover, determining theprevalence of a condition is crucial for assessing itsnegative impacts on society and designing healthcareprograms (12).Early diagnosis of hearing loss in children and timely treatment can improve infants’ health status, their po­tentials, and cognitive abilities. Moreover, through de­termining the risk factors for sensorineural hearing loss(SNHL) during the fetal period and at birth, it is possibleto eliminate these risk factors and prevent the adverseconsequences (14). 
2. Objectives So far, no precise data has been reported regarding the number of neonates with SNHL in Iran. Therefore, we aimed to determine the prevalence of SNHL and the associated risk factors in neonatal wards and neonatal intensive care units (NICUs) of governmental hospitals, affiliated to Golestan University of Medical Sciences. We also attempted to promote hearing loss prevention anddiagnosis in neonates. 
3. Patients and Methods 
In this cross-sectional study, 870 neonates, who were eli­gible for the research, were selected via non-random con­venience sampling during the study period. The subjectswere selected among hospitalized patients in the neona­tal wards and NICUs of Taleghani and Dezyani Education­al Centers (with 30 beds in NICUs and 35 beds in neonatalwards) in Gorgan, Iran during 2010 - 2011.The sample size was calculated at 754 subjects, based on the comparison of main variables (α = 0.05, β = 0.2, P =0.06, d = 0.1, and N = 1500). Finally, considering a 15% drop­out rate, the sample size was calculated to be 870 subjects.The inclusion criteria were as follows: 1) being affected byat least one of the probable risk factors for SNHL, e.g., low birth weight and asphyxia during the neonatal period; 2)receiving intensive neonatal care for more than 48 hours;3) pathological jaundice (bilirubin level deviating fromthe normal range, considering the neonate’s age and weight); and 4) administration of ototoxic drugs such as aminoglycoside and furosemide. Also, patients were in­cluded in case the Otoacoustic Emissions (OAEs) at birthwere normal. The exclusion criteria were as follows: 1) neonate’s deathbefore discharge; 2) abnormal results of automated au­ditory brainstem response (AABR) at admission; 3) oxo­plasmosis, other (syphilis, varicella-zoster, parvovirus 
B19), Rubella, Cytomegalovirus, and Herpes (TORCH) in­fections; 4) chromosomal abnormalities; 5) craniofacialanomalies; and 6) absence from the audiometric test at the time of discharge (20-22).The AABR test was performed for all the neonates uponadmission, and a form of neonatal characteristics was completed. The data included neonatal age, gestationalage, birth weight, sex, duration of hospitalization, cra­niofacial anomalies, pathological jaundice, serum bili­rubin level, type of used ototoxic drugs (e.g., gentami­cin, amikacin, tobramycin, vancomycin, or furosemide),and duration of ototoxic treatment. Before hospital dis­charge, all the infants were evaluated using the AABR test.For neonates with abnormal AABR results, the Auditory Brainstem Response (ABR) test was performed on the day of discharge.All audiometric tests were performed by a professionalaudiometrist, blinded to the study procedures. In thisstudy, ABR was in the frequency range of 1000 - 3000 Hz. Clicks of alternating polarity were used (unilateral stim­ulation) with a frequency of 80 pulses per second and 35, 40, and 45 dB intensities. The waves were generated, based on 3000 trials in 10 milliseconds (ms), using anaudioscreener by Grason Stadler Incorporation (MadsenAccuScreen 1077, GN Otometrics, USA).The present study was approved by the ethics commit­tee of Golestan university of medical sciences. Before starting the study, the objectives were explained to the parents, and informed consents were obtained from themother or father. The collected data were presented as measures of cen­tral tendency and dispersion and were analyzed using SPSS version 11.5. To determine the statistical differences among the variables, Chi-square test was used for quali­tative variables and independent t-test for quantitative variables (considering the normal distribution of data). Normality of the data was assessed by Kolmogorov-Smirnov test. Also, the odds ratios (ORs) were calculated through logistic regression test. P-value less than 0.05was considered statistically significant (95% CI). 
4. Results In this cross-sectional study, 56.4% of the subjects werefemales, and the mean age of the neonates upon admis­sion was 3.75 ± 4.86 days (age range: 0 - 29 days). Among870 subjects, 40 cases were excluded due to abnormalAABR results at admission, 20 cases due to death beforehospital discharge, 10 cases due to congenial infec­tions and anomalies, and 9 cases due to early dischargeand absence from the hearing test (withdrawal rate =9.08%).Finally, the data related to 791 neonates was analyzed. In total, 29.3% (n = 232) of the subjects were hospitalized within the first hours after birth. The mean length of hos­pital stay was 9.63 ± 1.1 days; the subjects were hospital­ized for 3.50 ± 10.21 days in the NICUs and 6.1 ± 5.27 days 
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(range: 0 - 48 days) in the neonatal wards. Tables 1 and 2 demonstrate the distribution of clinical interventions, as well as subjects’ demographic and clinical character­istics. Moreover, the results of hearing tests are depicted in Table 3. The statistical analysis showed no significant associa­tion between SNHL and neonates’ age (P = 0.52), sex (P =0.5), or sepsis (P = 0.94). However, SNHL was significantly associated with gestational age (P = 0.045), birth weight(P < 0.001), length of hospital stay (P < 0.001), pathologi­cal jaundice (P = 0.033), antibiotic treatments (P = 0.007),and total serum bilirubin level (P = 0.01).Moreover, a significant association was found be­tween SNHL and use of gentamicin, amikacin, tobra­mycin, and vancomycin (P < 0.001). Also, there was asignificant correlation between SNHL and duration ofantibiotic treatments (P < 0.001). However, SNHL wasnot significantly associated with furosemide adminis­tration or duration of furosemide treatment (P = 0.78and P = 0.76, respectively). Additionally, binary logisticregression analysis was performed in order to controlthe confounding variables and determine the odds ra­tios (Table 4). 
Table 1. Distribution of Clinical Interventions and Demographic Characteristics 
Variables Range Valuesa 
Age, d 0 - 29 3.75 ± 4.86 
Serum bilirubin level, mg/dL 6 - 35 14.12 ± 6.39 
Amikacin use, d 0 - 28 3.75 ± 5.71 
Vancomycin use, d 0 - 22 1.27 ± 4.11 
Length of hospital stay, d 1 - 110 9.63 ± 1.1 
Gentamicin use, d 0 - 29 2.73 ± 4.62 
Tobramycin use, d 0 - 15 0.15 ± 1.44 
Furosemide use, d 0 - 7 0.01 ± 0.27 
aData are presented as mean ± SD. 
Table 3. The Results of Neonates’ Hearing Testsa,b 
Table 2. Distribution of Clinical Interventions and Demographic Characteristics (Categorical Variables)a 
Variables Valuesb 
Gestational age Preterm 419 (53.0) Term 372 (47.0) 
Body weight SGA 258 (32.6) AGA 510 (64.5) LGA 23 (2.9) 
Gender Male 345 (43.6) Female 446 (56.4) 
Pathological jaundice Icteric 431 (54.5) Non-icteric 360 (45.5) 
Sepsis Clinical sepsisc 367 (46.4) Suspected sepsisd 88 (11.2) Proven sepsise 9 (1.1) No sepsis 327 (41.3) 
Antibiotic treatment Use of ototoxic drugs 463 (58.8) No use of ototoxic drugs 22 (2.8) 
Type of ototoxic antibioticsf Gentamicin 250 (31.6) Amikacin 282 (35.4) Tobramycin 10 (1.3) Vancomycin 76 (9.6) 
Furosemide Received 5 (0.6) Not received 786 (99.4) aAbbreviations: bLGA, Large for gestational age; cAGA, Appropriate for
gestational age; SGA, Small for gestational age.
bData are presented as No (%).
cClinical manifestations of sepsis plus negative blood culture and 
negative C-reactive protein (CRP).
dClinical manifestations of sepsis, positive blood culture (often caused 
by contamination), and at least two positive blood tests, or CRP > 6
mg/L, or abnormal chest x-ray results, or positive cerebrospinal fluid 
culture, based on birth records.
eClinical manifestation of sepsis plus positive blood culture and 
common pathogens of neonatal infections (23, 24).
fSome neonates were administered two antibiotics simultaneously.
 

Auditory Tests Defects in the Left Ear Defects in the Right Ear Defects in Both Ears Healthy Ears 
AABR at hospitalization 19 (2.4) 11 (1.4) 10 (1.3) 751 (94.9) 
AABR at discharge 2 (0.3) 3 (0.4) 21 (2.7) 765 (96.6) 
Final ABR 2 (0.3) 3 (0.4) 21 (2.7) 765 (96.6) 
aAbbreviations: AABR, Automated Auditory Brainstem Response; ABR, Auditory Brainstem Response.bData are presented as No (%). 
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Table 4. Binary Logistic Regression of Factors Associated With Sensorineural Hearing Loss (SNHL) 
Variables OR 95% CI P-Value 
Gestational age, d 2.48 1.03 - 5.97 0.04 
Birth weight, g 2.59 0.71 - 3.91 < 0.001 
Length of hospital stay, d 2.87 1.97 - 4.11 < 0.001 
Pathological jaundice 2.48 1.82 - 5.46 0.001 
Total bilirubin level, mg⁄dL 3.49 1.37 - 6.38 0.001 
Use of antibiotics 4.97 1048 - 16.71 0.009 
Gentamicin 3.63 1.62 - 8.12 0.002 
Amikacin 4.27 1.83 - 9.95 0.001 
Tobramycin 14.12 3.43 - 58.12 < 0.001 
Vancomycin 5.52 2.37 - 12.85 < 0.001 
Duration of gentamicin treatment 3.17 1.03 - 7.35 0.001 
Duration of amikacin treatment 3.02 1.46 - 6.80 0.001 
Duration of tobramycin treatment 4.26 1.14 - 8.27 < 0.001 
Duration of vancomycin treatment 4.10 1.42 - 7.83 < 0.001 
5. Discussion In the current study, based on the final ABR results, 26 cases (3.4%) had SNHL, while in a study by Bayat in 2007, this type of hearing loss was reported in 7.6% of the sub­jects (25). Also, in a study by Pourarian in 2012, 13.7% of the participants suffered from hearing loss, which washigher than the expected rate. This discrepancy in theprevalence of SNHL might be related to differences in SNHL assessment methods (26). In addition, in studies byCoenraad in 2010, Ohl in 2009, Taghdiri in 2008, and Za­hedpasha in 2007, 3%, 4.55%, 4%, and 1.2% of the newborns were affected by SNHL, respectively (20, 27-29).The results of this study showed that birth weight, gesta­tional age, length of hospital stay, pathological jaundice, serum bilirubin level, use of ototoxic antibiotics (e.g., gentamicin, amikacin, tobramycin, and vancomycin), and duration of antibiotic treatment are risk factors for the development of adventitious SNHL. The ABR results showed that SNHL was significantly associated with thesevariables. However, SNHL was not significantly related to neonatal age, gender, sepsis, use of furosemide, or dura­tion of furosemide treatment. In a study by Ohl, the risk factors for SNHL includedsevere birth asphyxia, neurological disorders, TORCHinfections, family history of hearing loss, and neonatalage at screening; however, hearing loss was not asso­ciated with birth weight below 1500 g or birth before34 weeks of gestation (29). Furthermore, in a study byTaghdiri, poor AABR results were significantly associat­ed with hyperbilirubinemia and birth weight less than1500 g (28). Also, in a study by Amini, no statistical cor­relation was found between 5-minute Apgar score andabnormal OAE; however, a significant relationship was
found between the mean birth weight and abnormalOAE (30).In the current study, gestational age was significantlyassociated with SNHL, and a significant difference wasobserved between term and preterm newborns. How­ever, findings reported by Porto in 2011 were inconsis­tent with the present results, and auditory responses inABR tests were not significantly different between termand preterm infants; this discrepancy might be relatedto the small sample size of the mentioned study (31). Onthe other hand, the findings of a study by Casali in 2010were in agreement with the present results, and therewas a significant difference in ABR wave delays betweenterm and preterm newborns; also, an inverse correla­tion was found between gestational age and these de­lays (32).As previously mentioned, administration of ototoxic antibiotics significantly reduced the neonates’ hearingability. In fact, the longer course of antibiotic therapy was associated with a higher risk of SNHL. Similarly, Bayat in­troduced aminoglycosides as the cause of hearing loss in neonates (25). Moreover, in the study by Zahedpasha, 7 neonates (1.2%) had abnormal ABR results and only those,who had received furosemide, showed significant differ­ences in terms of SNHL (20). Contrarily, in the present study, furosemide administration and treatment course were not significantly associated with the prevalence of hearing loss, which might be due to the limited numberof subjects using this medication.According to previous studies, the prevalence of patho­logical jaundice and high bilirubin level were also im­portant risk factors for SNHL during the neonatal period. 
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In a study by Boo in 2008, 32 neonates (8.12%) presentedwith severe hyperbilirubinemia and unilateral or bilat­eral SNHL; however, there was no significant difference in peak serum bilirubin level between neonates with hear­ing loss and healthy subjects (33).In a study by Ahlfors and Parker in 2008, increasedserum unconjugated bilirubin level, unlike total bili­rubin, was associated with abnormal AABR responses;this might be due to the closer correlation between un­conjugated bilirubin concentration and bilirubin neu­rotoxicity, compared to total bilirubin level (34). Also,Mojtabaei et al. in 2008 showed that increased level ofindirect bilirubin (> 20 mg/dL) causes hearing impair­ment in neonates and increases the I-V interpeak laten­cy (35). Additionally, in a study by Akbari and Keyhani in2005 - 2006, 15% of newborns with severe hyperbilirubi­nemia (> 20 mg/dL) presented with auditory neuropa­thy (36).The strengths of the present study included the high participation rate, the longitudinal design, use of one single measurement tool, and performance of evalua­tions by one audiometrist, which could prevent mea­surement errors and observer bias. However, since the subjects were selected among hospitalized patients, wecannot generalize the findings to the whole population;this could be one limitation of the present study. Another shortcoming of this study was deviation of some vari­ables from the mean value and therefore, the need fornon-parametric tests, which are generally not as reliableas other tests. In conclusion, administration of ototoxic antibiotics, prolonged hospitalization, and long duration of treat­ment can increase the prevalence of SNHL in neonates. In addition, neonates with other risk factors such as ab­normal birth weight, preterm birth, and pathologicaljaundice are more susceptible to hearing loss and requiremore attentive care and long-term follow-ups. Therefore, timely detection and prevention of the mentioned risk factors is highly recommended.Additionally, proper control of maternal risk factors in pregnancy and timely prevention of abnormalities and fetal distress may play an important role in reducing the prevalence of hearing loss in infants. It seems that neo­nates receiving ototoxic therapies need to be screenedand continuously followed-up to prevent future compli­cations such as cognitive, behavioral, and developmental disorders. 
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